Xamoterol monotherapy in heart failure. The European 'Corwin' Group.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 1971596.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The effect of xamoterol as sole therapy was investigated in randomized, double-blind, placebo-controlled studies involving 425 patients with mild to moderate heart failure. When compared with placebo, xamoterol produced improvements in exercise capacity, clinical signs, symptoms and quality of life with a low incidence of adverse experiences. Xamoterol is effective as monotherapy in heart failure.
Medical subject headings
- Adrenergic beta-Agonists
- Cardiac Output, Low
- Propanolamines